|Articles|June 28, 2023
Are Nitrosamines a Concern for Biologic Manufacturers?
Author(s)SGS
This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
CNPV Deep Dive: Perspectives on Accelerated FDA Review From the C-Suite to the Manufacturing Floor
3
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 1: A Practical Application of Specification Equivalence
4
Is Pharma Solving the Right Problem with its Data Transformation Efforts?
5